Cagrilintide
Long-acting amylin analog
At a glance
What it is: Long-acting amylin analog.
Primary research applications:
- Weight management (as part of combination therapy)
- Glycemic control
Editorial summary: Cagrilintide on its own produces modest weight loss in Phase 2 trials, but its real role in the field is as the other half of CagriSema — a combination with semaglutide that shows additive weight-loss effects.
What is Cagrilintide?
Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. Native amylin has a half-life of only minutes; cagrilintide has been engineered to allow once-weekly subcutaneous dosing. It is under development by Novo Nordisk.[1]
Mechanism of action
Amylin acts on brainstem regions (area postrema and nucleus tractus solitarius) to slow gastric emptying and promote satiety. Cagrilintide activates amylin and calcitonin receptors, contributing to appetite suppression through a mechanism distinct from GLP-1 agonism — which is why combinations with GLP-1 agonists are of interest.
What the research shows
The peer-reviewed literature on Cagrilintide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Adds meaningful weight loss on top of GLP-1 therapy | Phase 1b combination data | Plausible |
| Reduces food intake through a non-GLP-1 mechanism | Mechanism data | Supported |
| Approved as monotherapy | Not approved as of 2026 | Unsupported |
Reported user experiences
How the research describes administration
Administered once weekly by subcutaneous injection in trials, with stepwise titration. Not approved for clinical use as of 2026.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cagrilintide is more interesting as a combination partner (CagriSema) than as a standalone. The mechanism is complementary to GLP-1, but the incremental benefit over semaglutide or tirzepatide monotherapy is still being defined by Phase 3 data.
Frequently asked questions
What is amylin and why target it?
Amylin is a 37-amino acid hormone co-secreted with insulin from pancreatic beta cells. It signals satiety through brainstem pathways separate from GLP-1. Targeting both systems simultaneously produces additive effects on food intake.
Is cagrilintide the same as pramlintide?
Both are amylin analogs, but pramlintide (Symlin) is a short-acting version approved for diabetes that requires multiple daily injections. Cagrilintide is engineered for once-weekly use.
Is cagrilintide available?
Not as an approved drug. Its primary clinical role is expected to be as part of CagriSema, which is still in late-stage development.
How much weight loss does cagrilintide produce alone?
Approximately 6–10% at 26 weeks in Phase 2 — roughly comparable to first-generation GLP-1 agonists, but below the newer incretin class.
References
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64:11183-11194. https://pubmed.ncbi.nlm.nih.gov/34320805/
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160-2172. https://pubmed.ncbi.nlm.nih.gov/34774493/
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 2021;397:1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/